Pfizer, Inc. announced on January 6 that the U.S. Food and Drug Administration (FDA) has accepted its application for the 20-valent pneumococcal vaccine (20vPnC) for the supplemental Biologics License Application (sBLA) for priority review.
The 20-valent pneumococcal vaccine is used to prevent invasive pneumococcal disease (IPD) and can be administered to infants and adolescents aged 6 weeks to 17 years.
The announcement stated that if approved, the vaccine would provide the maximum protection against pneumococcal diseases for infants and adolescents.